Levetiracetam Intrapharm Laboratories (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action reduces neuronal hyperexcitability and helps stabilise synaptic activity, thereby lowering the likelihood of seizure generation and spread.

The specific dose of levetiracetam is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for levetiracetam during pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. Breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with older antiepileptics such as carbamazepine or valproate, levetiracetam has a distinct mechanism (SV2A binding) and generally fewer drug‑enzyme interactions, which can simplify combination therapy. However, individual response and side‑effect profiles vary, so choice of therapy should be personalised.

Levetiracetam intravenous solution should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging. Do not freeze the solution; inspect for particulate matter before administration.

Levetiracetam is given by intravenous infusion. The infusion rate and total daily dose are prescribed by the treating physician, who may adjust based on renal function and clinical response. Administration should follow aseptic technique and standard IV infusion guidelines.

Serious risks include severe allergic reactions such as rash, swelling, or breathing difficulty, rare skin conditions like Stevens‑Johnson syndrome, and emergence of suicidal thoughts or depressive symptoms. Prompt medical evaluation is required if any of these occur.

Levetiracetam is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those taking interacting medications that significantly alter its plasma levels.